Press Releases
- Outrun Therapeutics unveils lead programme targeting HPV positive head and neck cancer and appoints renowned E3 ligase experts to Scientific Advisory Board (SAB) 17 Mar 2026
- Outrun Therapeutics expands leadership team with appointment of Matthew Fyfe as Chief Scientific Officer 13 Jan 2025
- Outrun Therapeutics launches with a $10m seed financing from M Ventures and MP Healthcare Venture Management to develop a protein stabilisation pipeline 18 Apr 2024